Los Angeles Capital Management LLC Sells 15,708 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Los Angeles Capital Management LLC trimmed its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 7.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 188,316 shares of the biopharmaceutical company's stock after selling 15,708 shares during the quarter. Los Angeles Capital Management LLC owned 0.15% of Catalyst Pharmaceuticals worth $4,567,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of CPRX. Park Square Financial Group LLC bought a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $29,000. Sound Income Strategies LLC bought a new stake in shares of Catalyst Pharmaceuticals in the first quarter valued at approximately $64,000. GAMMA Investing LLC lifted its position in Catalyst Pharmaceuticals by 26.2% in the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after purchasing an additional 579 shares during the period. Quarry LP bought a new position in Catalyst Pharmaceuticals in the fourth quarter worth $104,000. Finally, New Vernon Capital Holdings II LLC bought a new position in Catalyst Pharmaceuticals in the fourth quarter worth $122,000. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Stock Down 1.1%

Catalyst Pharmaceuticals stock traded down $0.24 during mid-day trading on Friday, hitting $20.78. 253,392 shares of the company were exchanged, compared to its average volume of 1,286,178. The business has a fifty day moving average of $23.03 and a 200 day moving average of $22.88. Catalyst Pharmaceuticals, Inc. has a 1-year low of $15.34 and a 1-year high of $26.58. The company has a market capitalization of $2.53 billion, a PE ratio of 13.22, a price-to-earnings-growth ratio of 0.88 and a beta of 0.66.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 2,324 shares of the stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $26.41, for a total transaction of $61,376.84. Following the completion of the transaction, the insider directly owned 42,681 shares in the company, valued at $1,127,205.21. This represents a 5.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Gary Ingenito sold 200,000 shares of the firm's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $23.68, for a total value of $4,736,000.00. Following the completion of the sale, the insider owned 68,873 shares of the company's stock, valued at approximately $1,630,912.64. This trade represents a 74.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 247,924 shares of company stock valued at $5,879,369 over the last quarter. Corporate insiders own 10.40% of the company's stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Six equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $32.83.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.